1. Home
  2. MBIO vs VRAX Comparison

MBIO vs VRAX Comparison

Compare MBIO & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBIO
  • VRAX
  • Stock Information
  • Founded
  • MBIO 2015
  • VRAX 2013
  • Country
  • MBIO United States
  • VRAX United Kingdom
  • Employees
  • MBIO N/A
  • VRAX N/A
  • Industry
  • MBIO Biotechnology: Pharmaceutical Preparations
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • MBIO Health Care
  • VRAX Health Care
  • Exchange
  • MBIO Nasdaq
  • VRAX Nasdaq
  • Market Cap
  • MBIO 7.3M
  • VRAX 7.3M
  • IPO Year
  • MBIO N/A
  • VRAX 2022
  • Fundamental
  • Price
  • MBIO $2.80
  • VRAX $1.90
  • Analyst Decision
  • MBIO Strong Buy
  • VRAX
  • Analyst Count
  • MBIO 1
  • VRAX 0
  • Target Price
  • MBIO $100.00
  • VRAX N/A
  • AVG Volume (30 Days)
  • MBIO 405.3K
  • VRAX 282.7K
  • Earning Date
  • MBIO 03-10-2025
  • VRAX 02-05-2025
  • Dividend Yield
  • MBIO N/A
  • VRAX N/A
  • EPS Growth
  • MBIO N/A
  • VRAX N/A
  • EPS
  • MBIO N/A
  • VRAX N/A
  • Revenue
  • MBIO N/A
  • VRAX $84,872.00
  • Revenue This Year
  • MBIO N/A
  • VRAX $5,169.18
  • Revenue Next Year
  • MBIO N/A
  • VRAX $66.97
  • P/E Ratio
  • MBIO N/A
  • VRAX N/A
  • Revenue Growth
  • MBIO N/A
  • VRAX 7.03
  • 52 Week Low
  • MBIO $2.40
  • VRAX $0.60
  • 52 Week High
  • MBIO $74.50
  • VRAX $9.00
  • Technical
  • Relative Strength Index (RSI)
  • MBIO 29.74
  • VRAX 49.13
  • Support Level
  • MBIO $2.40
  • VRAX $1.58
  • Resistance Level
  • MBIO $3.04
  • VRAX $2.10
  • Average True Range (ATR)
  • MBIO 0.65
  • VRAX 0.25
  • MACD
  • MBIO 0.06
  • VRAX 0.01
  • Stochastic Oscillator
  • MBIO 9.30
  • VRAX 47.88

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Share on Social Networks: